These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 34524886)

  • 1. Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection.
    Leuzinger K; Osthoff M; Dräger S; Pargger H; Siegemund M; Bassetti S; Bingisser R; Nickel CH; Tschudin-Sutter S; Khanna N; Rentsch K; Battegay M; Egli A; Hirsch HH
    J Clin Microbiol; 2021 Nov; 59(12):e0138121. PubMed ID: 34524886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs.
    Van Elslande J; Decru B; Jonckheere S; Van Wijngaerden E; Houben E; Vandecandelaere P; Indevuyst C; Depypere M; Desmet S; André E; Van Ranst M; Lagrou K; Vermeersch P
    Clin Microbiol Infect; 2020 Nov; 26(11):1557.e1-1557.e7. PubMed ID: 32745595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
    Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
    J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.
    Yun S; Ryu JH; Jang JH; Bae H; Yoo SH; Choi AR; Jo SJ; Lim J; Lee J; Ryu H; Cho SY; Lee DG; Lee J; Kim SC; Park YJ; Lee H; Oh EJ
    Ann Lab Med; 2021 Nov; 41(6):577-587. PubMed ID: 34108285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
    Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins.
    Favresse J; Cadrobbi J; Eucher C; Elsen M; Laffineur K; Dogné JM; Douxfils J
    J Med Virol; 2021 Apr; 93(4):2262-2269. PubMed ID: 33200836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
    Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
    Front Immunol; 2020; 11():609242. PubMed ID: 33424863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of SARS-CoV-2 IgG assays in India.
    Chaudhuri S; Thiruvengadam R; Chattopadhyay S; Mehdi F; Kshetrapal P; Shrivastava T; Desiraju BK; Batra G; Kang G; Bhatnagar S;
    J Clin Virol; 2020 Oct; 131():104609. PubMed ID: 32866811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
    Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain.
    Poljak M; Oštrbenk Valenčak A; Štamol T; Seme K
    J Clin Virol; 2021 Apr; 137():104784. PubMed ID: 33711693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet.
    Krüttgen A; Cornelissen CG; Dreher M; Hornef MW; Imöhl M; Kleines M
    J Virol Methods; 2021 Jan; 287():113978. PubMed ID: 32979407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer.
    Chan CW; Yi X; Lenza M; Baldwin AD; Jakalski J; Tesic V; Yeo KJ
    Am J Clin Pathol; 2022 Jan; 157(1):109-118. PubMed ID: 34463315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use.
    Prince HE; Givens TS; Lapé-Nixon M; Clarke NJ; Schwab DA; Batterman HJ; Jones RS; Meyer WA; Kapoor H; Rowland CM; Haji-Sheikhi F; Marlowe EM
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32817144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19.
    Flinck H; Rauhio A; Luukinen B; Lehtimäki T; Haapala AM; Seiskari T; Aittoniemi J
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115197. PubMed ID: 32977117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays.
    Merrill AE; Jackson JB; Ehlers A; Voss D; Krasowski MD
    J Appl Lab Med; 2020 Nov; 5(6):1351-1357. PubMed ID: 32717056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring.
    Moeller ME; Engsig FN; Bade M; Fock J; Pah P; Soerensen AL; Bang D; Donolato M; Benfield T
    Microbiol Spectr; 2022 Apr; 10(2):e0039622. PubMed ID: 35357223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
    Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
    Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to SARS-CoV-2 nucleocapsid and spike proteins in hospitalized patients with COVID-19: A multicenter, retrospective, cross-sectional study in Japan.
    Hibino M; Watanabe S; Tobe S; Maeda K; Horiuchi S; Nishiguchi S; Iwase A; Uryu K; Kobayashi S; Kondo T
    Respir Investig; 2022 Mar; 60(2):256-263. PubMed ID: 34924308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.